Logo image of WRAC

WILLIAMS ROWLAND ACQUISITION (WRAC) Stock Fundamental Analysis

USA - NYSEARCA:WRAC - US96951B1026 - Common Stock

10.5 USD
-0.07 (-0.66%)
Last: 2/29/2024, 8:14:13 PM
Fundamental Rating

1

Overall WRAC gets a fundamental rating of 1 out of 10. We evaluated WRAC against 0 industry peers in the Unkown industry. Both the profitability and financial health of WRAC have multiple concerns. WRAC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year WRAC was profitable.
In the past year WRAC has reported a negative cash flow from operations.
WRAC Yearly Net Income VS EBIT VS OCF VS FCFWRAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 0 500K -500K 1M -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA 3.37%
ROE 5.32%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WRAC Yearly ROA, ROE, ROICWRAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 2 -2

1.3 Margins

WRAC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WRAC Yearly Profit, Operating, Gross MarginsWRAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

2

2. Health

2.1 Basic Checks

WRAC has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, WRAC has a worse debt to assets ratio.
WRAC Yearly Shares OutstandingWRAC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M 20M 25M
WRAC Yearly Total Debt VS Total AssetsWRAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

WRAC has an Altman-Z score of 4.51. This indicates that WRAC is financially healthy and has little risk of bankruptcy at the moment.
WRAC has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 4.51
ROIC/WACCN/A
WACCN/A
WRAC Yearly LT Debt VS Equity VS FCFWRAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

WRAC has a Current Ratio of 0.11. This is a bad value and indicates that WRAC is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.11 indicates that WRAC may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
WRAC Yearly Current Assets VS Current LiabilitesWRAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 500K 1M 1.5M

More info and screens

1

3. Growth

3.1 Past

WRAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 143.92%, which is quite impressive.
EPS 1Y (TTM)143.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 1050.00, the valuation of WRAC can be described as expensive.
WRAC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.91.
Industry RankSector Rank
PE 1050
Fwd PE N/A
WRAC Price Earnings VS Forward Price EarningsWRAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WRAC Per share dataWRAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

WRAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WILLIAMS ROWLAND ACQUISITION

NYSEARCA:WRAC (2/29/2024, 8:14:13 PM)

10.5

-0.07 (-0.66%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.4%
Inst Owner Change0%
Ins Owners64.37%
Ins Owner Change0%
Market Cap87.67M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1050
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.05
P/tB 5.05
EV/EBITDA N/A
EPS(TTM)0.01
EY0.1%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0
BVpS2.08
TBVpS2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.37%
ROE 5.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z 4.51
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)143.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-66.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.99%
OCF growth 3YN/A
OCF growth 5YN/A